Aclaris Therapeutics (ACRS) Accumulated Depreciation & Amortization: 2017-2025
Historic Accumulated Depreciation & Amortization for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $5.0 million.
- Aclaris Therapeutics' Accumulated Depreciation & Amortization rose 6.50% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 million, marking a year-over-year increase of 11.37%. This contributed to the annual value of $4.8 million for FY2024, which is 15.45% up from last year.
- Latest data reveals that Aclaris Therapeutics reported Accumulated Depreciation & Amortization of $5.0 million as of Q3 2025, which was down 0.52% from $5.0 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $5.0 million in Q2 2025 and a low of $2.9 million during Q1 2021.
- For the 3-year period, Aclaris Therapeutics' Accumulated Depreciation & Amortization averaged around $4.6 million, with its median value being $4.6 million (2023).
- Data for Aclaris Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY climbed of 29.36% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' Accumulated Depreciation & Amortization stood at $3.4 million in 2021, then climbed by 18.92% to $4.0 million in 2022, then rose by 3.15% to $4.2 million in 2023, then rose by 15.45% to $4.8 million in 2024, then increased by 6.50% to $5.0 million in 2025.
- Its last three reported values are $5.0 million in Q3 2025, $5.0 million for Q2 2025, and $4.9 million during Q1 2025.